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ABSTRACT
Sunitinib is a chemotherapeutic agent that has been approved for renal cell carcinoma and gastrointestinal stromal tumors resistant to imatinib. It is usually well tolerated and severe gastrointestinal side effects are rare.
There are very few reports of sunitinib causing severe esophagitis, and only one of them was previously
reported as exfoliative esophagitis. We describe a case of severe sunitinib-induced exfoliative esophagitis that
resulted in overt gastrointestinal bleed.

INTRODUCTION
Sunitinib is an orally available multireceptor tyrosine kinase inhibitor with antiangiogenic activity. It targets
vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptors, and stem
cell factor receptors.1 Generally well tolerated, sunitinib was approved in 2005 for metastatic renal cell carcinoma and GI stromal tumors resistant to imatinib.2,3 The standard dose of sunitinib is 50 mg per day, 4
weeks on and 2 weeks off.1,2
Exfoliative esophagitis is a rare condition caused by the dissection and exfoliation of esophageal mucosa from submucosal tissues.4,5 The usual etiologies of exfoliative esophagitis are chemical, thermal, or physical trauma from
foods, from drugs like cyclooxygenase-2 (COX-2) inhibitors and nonsteroidal anti-inﬂammatory drugs, radiation,
endoscopy,4,5 or from dermatological conditions like pemphigus vulgaris.4 To date, only one case of exfoliative
esophagitis caused by sunitinib has been reported, thus making this a rare etiology, especially in its causation of
gastrointestinal (GI) bleed.5

CASE REPORT
A 66-year-old man presented to our hospital with a 1-day history of acute-onset solid- and liquid-phase dysphagia
and odynophagia as well as an episode of melena. He had a known history of stage IV renal cell carcinoma treated
with nephrectomy and sunitinib initiated 10 months prior to his presentation. His medical history was otherwise signiﬁcant for atrial ﬁbrillation managed with warfarin and gastroesophageal reﬂux disease managed with pantoprazole (40 mg daily) and sucralfate for many years. Admission hemoglobin was 10.6 g/dL, signiﬁcantly lower than his
baseline of 13.0 g/dL, and he had an international normalized ratio of 4.1.
An esophagogastroduodenoscopy (EGD) revealed extensive necrosis and ulcerated mucosa throughout the
esophagus, with oozing blood and clots in the distal esophagus (Figure 1). Given the diffuse nature of the
lesions, endoscopic intervention was not indicated. There were multiple openings in the wall of the esophagus that looked like ﬁstulas (Figure 2). There was no narrowing noted in the esophagus (luminal diameter
was estimated to be more than 20 mm), and the gastroesophageal junction was traversed easily. No discrete masses were noted in the esophagus. There was mild esophagitis proximal to the area of necrosis.
Multiple biopsies were performed. The remainder of the examination showed a normal stomach and mild
duodenitis in the bulb.
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Figure 1. EGD revealed (A) extensive necrosis and ulcerated mucosa
throughout the esophagus with (B) oozing blood and clots in the distal
esophagus.

An omnipaque/barium esophagram showed multiple ﬁlling
defects within the mid- to distal esophagus, as well as
areas of mucosal irregularity possibly related to ulceration
(Figure 3). The lack of contrast extravasation ruled out
active ﬁstulas. Pathologic examination of the biopsy specimens showed partially necrotic fragments of squamous
mucosa, extensive acute inﬂammation, and ﬁbrinous exudate. These morphologic ﬁndings were consistent with
exfoliative esophagitis.
We suspected that sunitinib was responsible for these
ﬁndings and promptly discontinued this medication.
Pantoprazole was increased to 40 mg twice daily to aid in
esophageal healing. The patient’s dysphagia improved over
the next 3 days. He remained stable with no further GI
bleeding and was discharged home. While on high-dose pantoprazole, the patient was restarted on a reduced dose of
sunitinib 4 weeks later, which was well tolerated. Repeat
EGD 7 weeks later demonstrated complete healing of the
esophageal ulceration and necrosis (Figure 4). There were
no strictures noted on this EGD.

Figure 3. Omnipaque/barium esophagram showed multiple ﬁlling
defects within the mid- to distal esophagus, as well as areas of mucosal
irregularity possibly related to ulceration.

DISCUSSION

Figure 2. EGD showing a possible ﬁstulous opening.
ACG Case Reports Journal / Volume 3 / Issue 4

The efﬁcacy and safety of sunitinib for patients with metastatic renal cell carcinoma or GI stromal tumors have been
well documented.5 The non-GI side effects are usually mild
acgcasereports.gi.org

2

Gayam et al

Sunitinib-Induced Exfoliative Esophagitis

healing and increases the vulnerability of the mucosa.5
Additionally, as seen in rat models, COX-2 is an important inducer of VEGF in the esophageal mucosa and delays ulcer
healing when exposed to nonsteroidal anti-inﬂammatory
drugs.5,9
Our patient had no underlying conditions predisposing him
to exfoliative esophagitis, and sunitinib was therefore considered as the cause. We encourage clinicians to consider medications, especially chemotherapeutic agents, as a cause for
severe esophagitis and occult or overt GI bleeding.
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and commonly include asthenia, stomatitis, hypertension, left
heart failure, and skin manifestations, including hand-foot skin
reaction.1,2,5,6 Gastrointestinal side effects include diarrhea,
nausea, gastroesophageal reﬂux, mild esophagitis, and mild
gastritis.1,5 Esophagitis/gastritis is thought to be due to mucosal irritation by peptic acid secretion.1 In most cases, either
mild or no visible endoscopic ﬁndings can be seen.1,2,5
Patients may also report symptoms of dysphagia and odynophagia.1 Esophagitis with extensive exfoliation is a very rare
manifestation of severe esophageal mucositis.5
The mechanism of the development of exfoliative esophagitis
is not yet known. It is presumed that sunitinib promotes the
development of gastroesophageal reﬂux, which then leads to
severe esophagitis. It is believed to be related to VEGF and
mitogen-activated protein kinase pathways that are involved
in mucosal defense from gastric acid and repair of mucosal
lesions.1,2 VEGF receptors are expressed in normal esophageal mucosa and are responsible for restoring connective tissue and angiogenesis in acutely and chronically injured
mucosa.6,7,8 Acute and chronic injury can increase the expression of VEGF.5,8 VEGF inhibition results in impaired mucosal
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